Increased Risk of Aortic Valve Stenosis in Patients With Psoriasis

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker; COPD, chronic obstructive pulmonary disease.

^aAtherosclerotic heart disease, myocardial infarction, stroke, and atherosclerotic vascular disease.

Authors and Disclosures

Usman Khalid¹*, Ole Ahlehoff^1,2, Gunnar Hilmar Gislason^1,3,4, Lone Skov^4,5, Christian Torp-Pedersen^4,6 and Peter Riis Hansen^1,4

¹Department of Cardiology, Gentofte Hospital, University of Copenhagen, Post 635, Niels Andersens Vej 65, Hellerup DK-2900, Denmark; ²Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen, Denmark; ³National Institute of Public Health, University of Southren Denmark, Copenhagen, Denmark; ⁴Faculty of Health Sciences, University of Copenhagen, Copenhagen DK-2200, Denmark; ⁵Department of Dermatology, Gentofte Hospital, University of Copenhagen, Hellerup DK-2900, Denmark; and ⁶Science and Technology, Institute of Health, Aalborg University, Aalborg, Denmark

*Corresponding author
Tel: +45 27830081, Fax: +45 70201281, Email: usman.khalid@regionh.dk

†Presentation at Scientific session: The abstract of the present study has orally been presented as a moderated poster at ESC Congress 2014 (Barcelona); however, the data have never been published anywhere.

Authors contributions'
Conceived and designed the experiments: U.K., O.A., G.H.G., L.S., C.T.-P., and P.R.H. Analyzed the data: U.K., O.A., G.H.G., and P.R.H. Wrote the manuscript: U.K., O.A., and P.R.H. Revision of manuscript for critical contents: U.K., O.A., G.H.G., L.S., C.T.-P., and P.R.H. All authors approved the final manuscript.

Funding
The study was financially supported by unrestricted grants from the LEO Foundation. G.H.G. is supported by an unrestricted clinical research scholarship from the Novo Nordisk Foundation. The sponsors had no influence on data collection, no access to the data, and no influence on the decision to submit.

Conflict of interest
L.S. has received honoraria as consultant and/or speaker for Abbott, Janssen-Cilag, MSD, Lilly, Novartis, Pfizer, and LEO Pharma. O.A. has received honoraria as speaker for Abbott, Pfizer, and Janssen-Cilag. P.R.H. has received honoraria as speaker for Abvie and MSD. G.H.G. has received research grants from Bayer, Pfizer, AstraZeneca boehringer-Ingelheim, and Bristol Meyer Squibb (BMS) and speaker honoraria from Pfizer, AstraZeneca, and BMS.

Sidebar

Translational Perspectives

Psoriasis is a chronic systemic inflammatory disease associated with a range of comorbidities including cardiovascular diseases. It is possible that this increased risk is driven by an overlap of inflammatory mechanisms. The current results suggest that patients with psoriasis have a disease severity-dependent increased risk of AS that is not explained by traditional cardiovascular risk factors. Additional studies are needed to define the mechanisms underlying the association between psoriasis and AS.